Charmaine Lykins is a seasoned executive with 30+ years of experience in the pharmaceutical industry across multiple therapeutic areas. She is currently Chief Executive Officer of Transneural Therapeutics and a Commercial Strategy Advisor to several privately held biotech companies. Over the past five years she has held pivotal commercial roles across public and privately held companies during times of exponential growth, including Chief Commercial Officer for industry trailblazers such as Karuna Therapeutics, acquired by BMS in 2023, and MapLight Therapeutics. In these capacities, Charmaine has been instrumental in building and leading the organizational competences necessary to commercialize new products, including Karuna’s strategic and operational launch capabilities for Cobenfy, approved in late 2024 for schizophrenia. Prior to Karuna, Charmaine was Chief Marketing Officer and Head of Global Product Planning at Acadia Pharmaceuticals. Earlier in her career, she held commercial roles of increasing responsibility at companies recognized as the top innovators and leaders in their therapeutic area during the time she was in role. These include leadership roles at Lundbeck, Eli Lilly and Sunovion (now Sumitomo Pharma). Her career spans the commercial strategy and execution of 10 product launches across the United States and global markets.